MANNITOL

/static/temp/default.svg

Search structure


Trade Names	ARIDOL ARIDOL KIT MANNITOL 10% MANNITOL 10% IN PLASTIC CONTAINER MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER MANNITOL 15% MANNITOL 15% IN PLASTIC CONTAINER MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45% MANNITOL 20% MANNITOL 20% IN PLASTIC CONTAINER MANNITOL 25% MANNITOL 5% MANNITOL 5% IN PLASTIC CONTAINER MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% OSMITROL 10% IN WATER OSMITROL 10% IN WATER IN PLASTIC CONTAINER OSMITROL 15% IN WATER OSMITROL 15% IN WATER IN PLASTIC CONTAINER OSMITROL 20% IN WATER OSMITROL 20% IN WATER IN PLASTIC CONTAINER OSMITROL 5% IN WATER OSMITROL 5% IN WATER IN PLASTIC CONTAINER RESECTISOL RESECTISOL IN PLASTIC CONTAINER
Synonyms	Alexitol sodium Aridol kit Bronchitol Cordycepic acid Crystalline mannitol extra-fine Crystalline mannitol fine Crystalline mannitol standard D-(-)-mannitol D-mannitol Diosmol E-421 E421 INS NO.421 INS-421 Isomalt impurity, mannitol- Manna sugar Mannite Mannitol Mannitol 200 Mannitol 2080 Mannitol 25 Mannitol 300 Mannitol 35 Mannitol 60 Mannitol m300 Mannitol, d- Mannitolum Mannogem 2080 NSC-407017 Osmitrol Pearlitol 160 c Pearlitol 200 sd Pearlitol 25 c Pearlitol 300 dc Pearlitol 50 c Resectisol
Status
Molecule Category	Free-form
ATC	A06AD16 B05BC01 B05CX04 R05CB16 V04CX04
UNII	3OWL53L36A
EPA CompTox	DTXSID30858955


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	FBPFZTCFMRRESA-KVTDHHQDSA-N
Smiles	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
InChI	InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C6H14O6
Molecular Weight	182.17
AlogP	-3.59
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	6.0
Number of Rotational Bond	5.0
Polar Surface Area	121.38
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	12.0

Assay Description	Organism	Bioactivity	Reference
Compound was tested for inhibition of Human acrosin by polyols	None	29.0 %
Compound was tested for its ability to inhibit DNA strand scission induced by resveratrol and Cu2+, at concentration 50 mM	Escherichia coli	0.6 %
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	Homo sapiens	-1.4 %
Antioxidant activity assessed as inhibition of hydroxyl radical at 100 ug/mL	None	48.0 %
Antioxidant activity assessed as inhibition of microsomal lipid peroxidation at 100 ug/mL	None	45.0 %
Antioxidant activity assessed as inhibition non-enzymatic reactants generated hydroxyl radical production at 100 ug/ml by spectrophotometry	None	52.0 %
Antioxidant activity assessed as inhibition non-enzymatic reactants generated hydroxyl radical production at 100 ug/ml after 90 mins by spectrophotometry	None	40.0 %
Antioxidant activity assessed as inhibition of hydroxyl radical generation at 200 ug/ml by spectrophotometry	None	41.0 %
Antioxidant activity assessed as inhibition of hydroxy radical generation at 100 ug/ml after 90 min by thiobarbuteric acid method	None	-42.0 %
Antioxidant activity assessed as inhibition of microsomal lipid peroxidation at 200 ug/mL by spectrophotometric analysis relative to control	None	49.0 %
Antioxidant activity assessed as inhibition of hydroxyl radical generation at 200 ug/mL after 90 mins by spectrophotometric analysis relative to control	None	49.0 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	18.6 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.03 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.03 %

Related Entries

Cross References

Resources	Reference
ChEBI	16899
ChEMBL	CHEMBL689
DrugBank	DB00742
DrugCentral	935
FDA SRS	3OWL53L36A
Human Metabolome Database	HMDB0000765
KEGG	C00392
PDB	MTL
PubChem	6251
SureChEMBL	SCHEMBL919
ZINC	ZINC000002041302

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).